DRIO - ラボスタイル・イノベ―ションズ （DarioHealth Corp.） ラボスタイル・イノベ―ションズDRIOのチャート
DRIOの企業情報
| symbol | DRIO |
|---|---|
| 会社名 | LabStyle Innovations Corp （ラボスタイル・イノベ―ションズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 ダリオ・ヘルス(DarioHealth Corp)（旧名：Labstyle Innovations Corp）はデジタル・ヘルス会社である。同社は、顧客にスマートフォンなどのモバイル機器を用する実験室テスト機能を有する技術の開発・商業化に従事する。同社の製品Dario Smart Diabetes Management Solution(Dario)は、ポケット・サイズ、血糖監視装置及びダリオスマートメーターと連合するソフトウェア・アプリケーションをベースするモバイル、リアルタイム、クラウドベース、糖尿病管理ソリューションである。 ラボスタイル・イノベ―ションズはイスラエルのデジタル・ヘルス・アプリ企業。モバイルで健康状態を検査するアプリの開発・商業化に従事する。糖尿病のためのアプリ「Dario」は、ランセット装置に特有の使い捨てテストカ―トリッジを利用、スマ―トフォンなどで血糖値を測定することが可能。血糖値の自己モニタリングとクラウドベ―スのサ―ビスを結合する。 DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. Its solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in Caesarea, Israel. |
| 本社所在地 | 9 Halamish Street Caesarea Industrial Park 3088900 ISR |
| 代表者氏名 | Yoav Shaked Yoav Shaked |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +972 3-622-2929 |
| 設立年月日 | 40756 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 21人 |
| url | http://mydario.com |
| nasdaq_url | https://www.nasdaq.com/symbol/drio |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -14.50800 |
| 終値（lastsale） | 0.93 |
| 時価総額（marketcap） | 19847679.63 |
| 時価総額 | 時価総額（百万ドル） 19.84768 |
| 売上高 | 売上高（百万ドル） 6.76800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 14.65468 |
| 当期純利益 | 当期純利益（百万ドル） -24.40300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 DarioHealth Corp revenues increased 72% to $3.8M. Net loss applicable to common stockholders increased from $845K to $9.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Revaluation of warrants decrease of 100% to $1K (income) General and administrative increase of 22% to $3.8M (expense). |
DRIOのテクニカル分析
DRIOのニュース
Dennis Matheis, President of Optima Health, a Multi-line Health Plan With More Than 850,000 Members and over 26,000 Providers, and Former President of Anthem Blue Cross and Blue Shield Central Region, Appointed to the Board of DarioHealth Corp 2020/07/06 12:30:00 PR Newswire
/PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the company has appointed veteran…
Dario Health to Host Key Opinion Leader Call on Digital Therapeutics for the Management of Diabetes and Other Chronic Conditions 2020/06/18 12:30:00 PR Newswire
NEW YORK, June 18, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that it will host a key opinion leader (KOL) call on digital therapeutics for the management of diabetes and other chronic conditions on Tuesday,…
DarioHealth Announces Participation in the Virtual Going Digital: Behavioral Health Tech Summit 2020/06/17 12:30:00 PR Newswire
/PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that Omar Manejwala, M.D., Chief Medical…
DarioHealth Presents New Studies Demonstrating Sustained Improvements in Blood Glucose and Blood Pressure Control in Users with Diabetes and Hypertension at the American Diabetes Association's 80th Scientific Sessions 2020/06/15 12:30:00 PR Newswire
NEW YORK, June 15, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leading global digital therapeutics (DTx) company, presented the results of two new studies at the American Diabetes Association's (ADA) 80th Scientific Sessions that showed sustained improvements in blood glucose…
DarioHealth Announces Two Remote Patient Monitoring (RPM) Agreements and Commences Enrollment 2020/06/11 12:30:00 PR Newswire
NEW YORK, June 11, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the company has signed its first two remote patient monitoring (RPM) agreements. Remote patient monitoring will allow treating physicians to…
DarioHealth to Report Financial Results for the First Quarter 2020 Results on May 12 2020/05/05 13:00:00 PR Newswire
/PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a pioneer in the global digital therapeutics market, announced it will…
DarioHealth Expands Offering to Include Behavioral Health 2020/05/04 12:30:00 PR Newswire
NEW YORK, May 4, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leading global digital therapeutics (DTx) innovator, announced today that it has expanded its offering on its chronic care platform application to include behavioral health coaching for stress, anxiety and…
DarioHealth Expands Remote Care Offering With Integration of Full-Service Telemedicine 2020/04/29 12:30:00 PR Newswire
NEW YORK, April 29, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in global digital therapeutics (DTx), announced today a new partnership with value-based telemedicine provider MediOrbis to expand Dario's existing service offering with a full suite of telemedicine…
Dario Diabetes Management Is Recognized as a Leading Application for Children/Young People Self-managing Healthcare During COVID-19 Pandemic 2020/03/25 12:30:00 PR Newswire
/PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a global digital therapeutics (DTx) innovator, announced today an endorsement from the U.K. based ORCHA,…
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company 2020/03/20 11:44:59 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) Biomerica, Inc. (NASDAQ: BMRA ) Centogene NV (NASDAQ: CNTG ) Gilead Sciences, Inc. (NASDAQ: GILD ) Imara Inc (NASDAQ: IMRA ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Down In The Dumps (Biotech stocks that hit 52-week lows March 19.) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aikido Pharma Inc (NASDAQ: AIKI ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Anika Therapeutics Inc (NASDAQ: ANIK ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Antares Pharma Inc (NASDAQ: ATRS ) Apyx Medical Corp (NASDAQ: APYX ) Arca Biopharma Inc (NASDAQ: ABIO ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) aTyr Pharma Inc (NASDAQ: LIFE ) AVEO Pharmaceuticals, Inc.
DarioHealth Reports Fourth Quarter and Year End 2019 Results 2020/03/17 10:30:00 PR Newswire
/PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a global digital therapeutics (DTx) innovator, today reported financial results for the fourth quarter and…
DarioHealth to Host Fourth Quarter 2019 Conference Call March 17, 2020 2020/03/12 12:30:00 PR Newswire
/PRNewswire/ -- Global digital therapeutics innovation leader DarioHealth Corp. (NASDAQ: DRIO) today announced it will release its fourth quarter and year end…
DarioHealth Appoints Two New Board Members 2020/03/05 13:30:00 PR Newswire
/PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the company has appointed Yadin Shemmer…
DarioHealth Digital Diabetes Management System is Now Available at Albertsons 2020/02/24 13:00:00 PR Newswire
NEW YORK, Feb. 24, 2020 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the launch of its digital therapeutics solution for managing chronic diseases such as diabetes and hypertension on Albertsons Marketplace….
DarioHealth® Presents New Clinical Study Outcomes Showing the Dario Digital Therapeutics Platform Helps Insulin Dependent Patients With Diabetes Better Manage Their Chronic Condition 2020/02/19 13:00:00 PR Newswire
/PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or "Dario"), a pioneer in the global digital therapeutics market, today presented a new…